LEVACETYLLEUCINE

Other

Brand names: AQNEURSA

Oral

12.1 Mechanism of Action The distinct molecular target for levacetylleucine in the treatment of NPC is unknown.

See full prescribing information

Contraindications

5 WARNINGS AND PRECAUTIONS Embryo-Fetal Toxicity : May cause fetal harm
Administration of levacetylleucine to pregnant rats and rabbits during the period of organogenesis caused an increase in embryo-fetal death (post implantation loss/resorption) and skeletal malformations at a dose that was approximately 1
The decision to continue or discontinue AQNEURSA treatment during pregnancy should consider the female’s need for AQNEURSA, the potential drug-related risks to the fetus, and the potential adverse outcomes from untreated maternal disease

4 documented side effects by frequency

Falls

0.1-1%

Insomnia

0.1-1%

Decreased Appetite

0.1-1%

Fatigue

0.1-1%

No community discussions found for LEVACETYLLEUCINE yet.

0 available comparisons

No comparisons yet.

Dosage Forms

Tablet

Route

Oral